Assessment of Microbiome Signature for Predicting Prognosis of Gastrointestinal Cancers

References

1. Wang D. DuBois R.N. Role of prostanoids in gastrointestinal cancer. J. Clin. Invest. 2018 128 7 2732 2742 10.1172/JCI97953 29733297
   [Google Scholar]
2. Nasrollahzadeh Sabet M. Movahedi Asl M. Kazemi Esfeh M. Nasrabadi N. Shakarami M. Alani B. Alimolaie A. Azhdari S. Cheraghi E. Mesenchymal stem cells as professional actors in gastrointestinal cancer therapy: From Naïve to genetically modified. Iran. J. Basic Med. Sci. 2021 24 5 561 576 34249257
   [Google Scholar]
3. Mokhtari R.B. Homayouni T.S. Baluch N. Morgatskaya E. Kumar S. Das B. Yeger H. Combination therapy in combating cancer. Oncotarget 2017 8 23 38022 38043 10.18632/oncotarget.16723 28410237
   [Google Scholar]
4. Greig R.G. Schein P.S. Therapy of gastrointestinal cancer. Scand. J. Gastroenterol. 1985 20 sup117 9 25 10.3109/00365528509092224 3912966
   [Google Scholar]
5. Avan A. Mehrabadi S. Velayati M. Zafari N. Hassanian S.M. Mobarhan M.G. Ferns G. Khazaei M. Growth-hormone-releasing hormone as a prognostic biomarker and therapeutic target in gastrointestinal cancer. Curr. Cancer Drug Targets 2023 23 5 346 353 10.2174/1568009623666221228094557 36582060
   [Google Scholar]
6. Zafari N. Velayati M. Nassiri M. Khazaei M. Hassanian S.M. Ferns G.A. Avan A. Pharmacological targeting of epithelial-to-mesenchymal transition in colorectal cancer. Curr. Pharm. Des. 2022 28 28 2298 2311 10.2174/1381612828666220728152350 35909286
   [Google Scholar]
7. Mehrabadi S. Salmani Izadi F. Pasha S. Pourali R. Khazaei M. Hassanian S.M. Ferns G.A. Avan A. The potential therapeutic applications of CRISPR/Cas9 in the treatment of gastrointestinal cancers. Curr. Mol. Med. 2024 24 10.2174/0115665240243076231116080113 38243923
   [Google Scholar]
8. Cox A.J. West N.P. Cripps A.W. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 2015 3 3 207 215 10.1016/S2213‑8587(14)70134‑2 25066177
   [Google Scholar]
9. Dikeocha I.J. Al-Kabsi A.M. Eid E.E.M. Hussin S. Alshawsh M.A. Probiotics supplementation in patients with colorectal cancer: A systematic review of randomized controlled trials. Nutr. Rev. 2021 80 1 22 49 10.1093/nutrit/nuab006 34027974
   [Google Scholar]
10. Ruan W. Engevik M.A. Spinler J.K. Versalovic J. Healthy human gastrointestinal microbiome: composition and function after a decade of exploration. Dig. Dis. Sci. 2020 65 3 695 705 10.1007/s10620‑020‑06118‑4 32067143
    [Google Scholar]
11. Damavandi S. Avan A. Zafari N. Velayati M. Mehrabadi S. Khazaei M. Hassanian S.M. Ferns G.A. Remodeling of the gut microbiota in colorectal Cancer and its association with obesity. Curr. Pharm. Des. 2023 29 4 256 271 10.2174/1381612829666230118123018 36654469
    [Google Scholar]
12. Mehrabadi S. Interaction between gut microbiota dysbiosis and multiple sclerosis. Int. J. Med. Investig. 2019 8 21 28
    [Google Scholar]
13. AL-Ishaq R.K. Liskova A. Kubatka P. Büsselberg D. Enzymatic metabolism of flavonoids by gut microbiota and its impact on gastrointestinal cancer. Cancers (Basel) 2021 13 16 3934 10.3390/cancers13163934 34439088
    [Google Scholar]
14. Long Y. Tang L. Zhou Y. Zhao S. Zhu H. Causal relationship between gut microbiota and cancers: A two-sample Mendelian randomisation study. BMC Med. 2023 21 1 66 10.1186/s12916‑023‑02761‑6 36810112
    [Google Scholar]
15. Shanahan F. Ghosh T.S. O’Toole P.W. The healthy microbiome—what is the definition of a healthy gut microbiome? Gastroenterology 2021 160 2 483 494 10.1053/j.gastro.2020.09.057 33253682
    [Google Scholar]
16. Hou K. Wu Z.X. Chen X.Y. Wang J.Q. Zhang D. Xiao C. Zhu D. Koya J.B. Wei L. Li J. Chen Z.S. Microbiota in health and diseases. Signal Transduct. Target. Ther. 2022 7 1 135 10.1038/s41392‑022‑00974‑4 35461318
    [Google Scholar]
17. Park E.M. Chelvanambi M. Bhutiani N. Kroemer G. Zitvogel L. Wargo J.A. Targeting the gut and tumor microbiota in cancer. Nat. Med. 2022 28 4 690 703 10.1038/s41591‑022‑01779‑2 35440726
    [Google Scholar]
18. Cheng W.Y. Wu C.Y. Yu J. The role of gut microbiota in cancer treatment: Friend or foe? Gut 2020 69 10 1867 1876 10.1136/gutjnl‑2020‑321153 32759302
    [Google Scholar]
19. Matson V. Chervin C.S. Gajewski T.F. Cancer and the microbiome—influence of the commensal microbiota on cancer, immune responses, and immunotherapy. Gastroenterology 2021 160 2 600 613 10.1053/j.gastro.2020.11.041 33253684
    [Google Scholar]
20. Kant R. Chandra L. Verma V. Nain P. Bello D. Patel S. Ala S. Chandra R. Antony M.A. Gut microbiota interactions with anti-diabetic medications and pathogenesis of type 2 diabetes mellitus. World J. Methodol. 2022 12 4 246 257 10.5662/wjm.v12.i4.246 36159100
    [Google Scholar]
21. Di Ciaula A. Bonfrate L. Portincasa P. The role of microbiota in nonalcoholic fatty liver disease. Eur. J. Clin. Invest. 2022 52 7 e13768 10.1111/eci.13768 35294774
    [Google Scholar]
22. Zafari N. Velayati M. Fahim M. Maftouh M. Pourali G. Khazaei M. Nassiri M. Hassanian S.M. Ghayour-Mobarhan M. Ferns G.A. Kiani M.A. Avan A. Role of gut bacterial and non-bacterial microbiota in alcohol-associated liver disease: Molecular mechanisms, biomarkers, and therapeutic prospective. Life Sci. 2022 305 120760 10.1016/j.lfs.2022.120760 35787997
    [Google Scholar]
23. Kostic A.D. Xavier R.J. Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014 146 6 1489 1499 10.1053/j.gastro.2014.02.009 24560869
    [Google Scholar]
24. Stojanov S. Berlec A. Štrukelj B. The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease. Microorganisms 2020 8 11 1715 10.3390/microorganisms8111715 33139627
    [Google Scholar]
25. Grigor’eva I.N. Gallstone disease, obesity and the firmicutes/bacteroidetes ratio as a possible biomarker of gut dysbiosis. J. Pers. Med. 2020 11 1 13 10.3390/jpm11010013 33375615
    [Google Scholar]
26. Chen J. Liu P. Sun J. Fusobacterium nucleatum: A potential biomarker and therapeutic target in colorectal cancer. J. Cancer Res. Ther. 2021 17 3 235 242
    [Google Scholar]
27. Yang X. Liu X. Zhu L. The role of Fusobacterium nucleatum in colorectal cancer development and progression. Gut Microbes 2020 11 6 1205 1218
    [Google Scholar]
28. Park H. Park J. Kim J. Faecalibacterium prausnitzii : A potential next-generation probiotic for gut health and beyond. Microorganisms 2019 7 12 594 31766493
    [Google Scholar]
29. Zhang Q. Zhou J. Li G. Microbial metabolites in colorectal cancer development and progression. Cancer Cell 2022 32 4 548 563
    [Google Scholar]
30. Johnson A.L. O’Brien C.J. O’Mahony D. The influence of the gut microbiome on host metabolism and immune function in health and disease. J. Immunol. 2018 201 7 1835 1843
    [Google Scholar]
31. Perez-Muñoz M.E. Arrieta M.C. Ramer-Tait A.E. Walter J. A critical assessment of the “sterile womb” and “in utero colonization” hypotheses: Implications for research on the pioneer infant microbiome. Microbiome 2017 5 1 48 10.1186/s40168‑017‑0268‑4 28454555
    [Google Scholar]
32. Vázquez-Castellanos J.F. León-Sicairos N. Segura-Cabrera A. Current knowledge of the human gut microbiota in health and disease. FEMS Microbiol. Lett. 2019 366 23 1 12
    [Google Scholar]
33. Wang Y. Cai S. Sun B. Gut microbiota as a potential target for cancer prevention and treatment. J. Exp. Clin. Cancer Res. 2021 40 1 1 12 33390177
    [Google Scholar]
34. Ortigão R. Pimentel-Nunes P. Dinis-Ribeiro M. Libânio D. Gastrointestinal microbiome–what we need to know in clinical practice. GE Port. J. Gastroenterol. 2020 27 5 336 351 10.1159/000505036 32999906
    [Google Scholar]
35. Li N.N. Bai C.M. Zhao L. Ge Y.P. Gut microbiome differences between gastrointestinal cancer patients and healthy people. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2019 41 5 636 645 31699194
    [Google Scholar]
36. Wierzbicka A. Mańkowska-Wierzbicka D. Mardas M. Stelmach-Mardas M. Role of probiotics in modulating human gut microbiota populations and activities in patients with colorectal cancer—A systematic review of clinical trials. Nutrients 2021 13 4 1160 10.3390/nu13041160 33915854
    [Google Scholar]
37. Brasiel P.G.A. Dutra Luquetti S.C.P. Peluzio M.C.G. Novaes R.D. Gonçalves R.V. Preclinical evidence of probiotics in colorectal carcinogenesis: A systematic review. Dig. Dis. Sci. 2020 65 11 3197 3210 10.1007/s10620‑020‑06062‑3 31960202
    [Google Scholar]
38. Engstrand L. Graham D.Y. Microbiome and gastric cancer. Dig. Dis. Sci. 2020 65 3 865 873 10.1007/s10620‑020‑06101‑z 32040665
    [Google Scholar]
39. Schulz C. Schütte K. Mayerle J. Malfertheiner P. The role of the gastric bacterial microbiome in gastric cancer: Helicobacter pylori and beyond. Therap. Adv. Gastroenterol. 2019 12 10.1177/1756284819894062 31897087
    [Google Scholar]
40. Yang J. Zhou X. Liu X. Ling Z. Ji F. Role of the gastric microbiome in gastric cancer: From carcinogenesis to treatment. Front. Microbiol. 2021 12 641322 10.3389/fmicb.2021.641322 33790881
    [Google Scholar]
41. Pereira-Marques J. Ferreira R.M. Pinto-Ribeiro I. Figueiredo C. Helicobacter pylori Infection, the gastric microbiome and gastric cancer. Adv Exp Med Biol 2019 1149 195 210 10.1007/5584_2019_366.
    [Google Scholar]
42. Rajilic-Stojanovic M. Figueiredo C. Smet A. Hansen R. Kupcinskas J. Rokkas T. Andersen L. Machado J.C. Ianiro G. Gasbarrini A. Leja M. Gisbert J.P. Hold G.L. Systematic review: Gastric microbiota in health and disease. Aliment. Pharmacol. Ther. 2020 51 6 582 602 10.1111/apt.15650 32056247
    [Google Scholar]
43. Dias-Jácome E. Libânio D. Borges-Canha M. Galaghar A. Pimentel-Nunes P. Gastric microbiota and carcinogenesis: The role of non-Helicobacter pylori bacteria - A systematic review. Rev. Esp. Enferm. Dig. 2016 108 9 530 540 10.17235/reed.2016.4261/2016 27604361
    [Google Scholar]
44. Gunathilake M. Lee J. Choi I.J. Kim Y.I. Kim J. Association between bacteria other than Helicobacter pylori and the risk of gastric cancer. Helicobacter 2021 26 5 e12836 10.1111/hel.12836 34268831
    [Google Scholar]
45. Nakano T. Dohi O. Takagi T. Naito Y. Fukui H. Miyazaki H. Yasuda T. Yoshida T. Azuma Y. Ishida T. Kitae H. Matsumura S. Takayama S. Mizuno N. Kashiwagi S. Mizushima K. Inoue R. Doi T. Hirose R. Inoue K. Yoshida N. Kamada K. Uchiyama K. Ishikawa T. Konishi H. Itoh Y. Characteristics of gastric mucosa-associated microbiota in patients with early gastric cancer after successful Helicobacter pylori eradication. Dig. Dis. Sci. 2023 68 12 4398 4406 10.1007/s10620‑023‑08154‑2 37875607
    [Google Scholar]
46. Sipponen P. Maaroos H.I. Chronic gastritis. Scand. J. Gastroenterol. 2015 50 6 657 667 10.3109/00365521.2015.1019918 25901896
    [Google Scholar]
47. Crafa P. Russo M. Miraglia C. Barchi A. Moccia F. Nouvenne A. Leandro G. Meschi T. De’ Angelis G.L. Di Mario F. From Sidney to OLGA: An overview of atrophic gastritis. Acta Biomed. 2018 89 8-S 93 99 30561425
    [Google Scholar]
48. Park J.Y. Seo H. Kang C.S. Shin T.S. Kim J.W. Park J.M. Kim J.G. Kim Y.K. Dysbiotic change in gastric microbiome and its functional implication in gastric carcinogenesis. Sci. Rep. 2022 12 1 4285 10.1038/s41598‑022‑08288‑9 35277583
    [Google Scholar]
49. Aviles-Jimenez F. Vazquez-Jimenez F. Medrano-Guzman R. Mantilla A. Torres J. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci. Rep. 2014 4 1 4202 10.1038/srep04202 24569566
    [Google Scholar]
50. Coker O.O. Dai Z. Nie Y. Zhao G. Cao L. Nakatsu G. Wu W.K.K. Wong S.H. Chen Z. Sung J.J.Y. Yu J. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut 2018 67 6 1024 1032 10.1136/gutjnl‑2017‑314281 28765474
    [Google Scholar]
51. Ferreira R.M. Pereira-Marques J. Pinto-Ribeiro I. Costa J.L. Carneiro F. Machado J.C. Figueiredo C. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut 2018 67 2 226 236 10.1136/gutjnl‑2017‑314205 29102920
    [Google Scholar]
52. Hu Y.L. Pang W. Huang Y. Zhang Y. Zhang C.J. The gastric microbiome is perturbed in advanced gastric adenocarcinoma identified through shotgun metagenomics. Front. Cell. Infect. Microbiol. 2018 8 433 10.3389/fcimb.2018.00433 30619779
    [Google Scholar]
53. Castaño-Rodríguez N. Goh K.L. Fock K.M. Mitchell H.M. Kaakoush N.O. Dysbiosis of the microbiome in gastric carcinogenesis. Sci. Rep. 2017 7 1 15957 10.1038/s41598‑017‑16289‑2 29162924
    [Google Scholar]
54. Eun C.S. Kim B.K. Han D.S. Kim S.Y. Kim K.M. Choi B.Y. Song K.S. Kim Y.S. Kim J.F. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter 2014 19 6 407 416 10.1111/hel.12145 25052961
    [Google Scholar]
55. Liu X. Shao L. Liu X. Ji F. Mei Y. Cheng Y. Liu F. Yan C. Li L. Ling Z. Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. EBioMedicine 2019 40 336 348 10.1016/j.ebiom.2018.12.034 30584008
    [Google Scholar]
56. Li Z.P. Liu J.X. Lu L.L. Wang L.L. Xu L. Guo Z.H. Dong Q.J. Overgrowth of Lactobacillus in gastric cancer. World J. Gastrointest. Oncol. 2021 13 9 1099 1108 10.4251/wjgo.v13.i9.1099 34616515
    [Google Scholar]
57. Vinasco K. Mitchell H.M. Kaakoush N.O. Castaño-Rodríguez N. Microbial carcinogenesis: Lactic acid bacteria in gastric cancer. Biochim Biophys Acta Rev Cancer Revis. Cancer 2019 1872 2 188309 10.1016/j.bbcan.2019.07.004.
    [Google Scholar]
58. Zhang Y. Shen J. Shi X. Du Y. Niu Y. Jin G. Wang Z. Lyu J. Gut microbiome analysis as a predictive marker for the gastric cancer patients. Appl. Microbiol. Biotechnol. 2021 105 2 803 814 10.1007/s00253‑020‑11043‑7 33404833
    [Google Scholar]
59. Pereira-Marques J. Ferreira R.M. Machado J.C. Figueiredo C. The influence of the gastric microbiota in gastric cancer development. Best Pract. Res. Clin. Gastroenterol. 2021 50-51 101734 10.1016/j.bpg.2021.101734 33975676
    [Google Scholar]
60. Chen X.H. Wang A. Chu A.N. Gong Y.H. Yuan Y. Mucosa-associated microbiota in gastric cancer tissues compared with non-cancer tissues. Front. Microbiol. 2019 10 1261 10.3389/fmicb.2019.01261 31231345
    [Google Scholar]
61. Liatsos C. Papaefthymiou A. Kyriakos N. Galanopoulos M. Doulberis M. Giakoumis M. Petridou E. Mavrogiannis C. Rokkas T. Kountouras J. Helicobacter pylori, gastric microbiota and gastric cancer relationship: Unrolling the tangle. World J. Gastrointest. Oncol. 2022 14 5 959 972 10.4251/wjgo.v14.i5.959 35646287
    [Google Scholar]
62. Sánchez-Alcoholado L. Ramos-Molina B. Otero A. Laborda-Illanes A. Ordóñez R. Medina J.A. Gómez-Millán J. Queipo-Ortuño M.I. The role of the gut microbiome in colorectal cancer development and therapy response. Cancers (Basel) 2020 12 6 1406 10.3390/cancers12061406 32486066
    [Google Scholar]
63. Rebersek M. Gut microbiome and its role in colorectal cancer. BMC Cancer 2021 21 1 1325 10.1186/s12885‑021‑09054‑2 34895176
    [Google Scholar]
64. Raoul P. Maccauro V. Cintoni M. Scarpellini E. Ianiro G. Gasbarrini A. Mele M.C. Rinninella E. Microbiota–gastric cancer interactions and the potential influence of nutritional therapies. Int. J. Mol. Sci. 2024 25 3 1679 10.3390/ijms25031679 38338956
    [Google Scholar]
65. Uchino Y. Goto Y. Konishi Y. Tanabe K. Toda H. Wada M. Kita Y. Beppu M. Mori S. Hijioka H. Otsuka T. Natsugoe S. Hara E. Sugiura T. Colorectal cancer patients have four specific bacterial species in oral and gut microbiota in common—A metagenomic comparison with healthy subjects. Cancers (Basel) 2021 13 13 3332 10.3390/cancers13133332 34283063
    [Google Scholar]
66. Yuan D. Tao Y. Wang H. Wang J. Cao Y. Cao W. Pan S. Yu Z. A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer. Invest. New Drugs 2022 40 5 884 894 10.1007/s10637‑022‑01263‑1 35727391
    [Google Scholar]
67. Dalal N. Jalandra R. Bayal N. Yadav A.K. Harshulika Sharma M. Makharia G.K. Kumar P. Singh R. Solanki P.R. Kumar A. Gut microbiota-derived metabolites in CRC progression and causation. J. Cancer Res. Clin. Oncol. 2021 147 11 3141 3155 10.1007/s00432‑021‑03729‑w 34273006
    [Google Scholar]
68. Louis P. Hold G.L. Flint H.J. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 2014 12 10 661 672 10.1038/nrmicro3344 25198138
    [Google Scholar]
69. Russo E. Bacci G. Chiellini C. Fagorzi C. Niccolai E. Taddei A. Ricci F. Ringressi M.N. Borrelli R. Melli F. Miloeva M. Bechi P. Mengoni A. Fani R. Amedei A. Preliminary comparison of oral and intestinal human microbiota in patients with colorectal cancer: A pilot study. Front. Microbiol. 2018 8 2699 10.3389/fmicb.2017.02699 29375539
    [Google Scholar]
70. Gao R. Gao Z. Huang L. Qin H. Gut microbiota and colorectal cancer. Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 5 757 769 10.1007/s10096‑016‑2881‑8 28063002
    [Google Scholar]
71. Li Y. Cao H. Fei B. Gao Q. Yi W. Han W. Bao C. Xu J. Zhao W. Zhang F. Gut microbiota signatures in tumor, para-cancerous, normal mucosa, and feces in colorectal cancer patients. Front. Cell Dev. Biol. 2022 10 916961 10.3389/fcell.2022.916961 35721506
    [Google Scholar]
72. Wu Y. Shi L. Li Q. Wu J. Peng W. Li H. Chen K. Ren Y. Fu X. Microbiota diversity in human colorectal cancer tissues is associated with clinicopathological features. Nutr. Cancer 2019 71 2 214 222 10.1080/01635581.2019.1578394 30843732
    [Google Scholar]
73. Narii N. Zha L. Sobue T. Kitamura T. Komatsu M. Shimomura Y. Shiba S. Mizutani S. Yamada T. Yachida S. Intestinal bacteria fluctuating in early-stage colorectal cancer carcinogenesis are associated with diet in healthy adults. Nutr. Cancer 2024 76 6 521 528 10.1080/01635581.2024.2344257 38642022
    [Google Scholar]
74. Ahn J. Sinha R. Pei Z. Dominianni C. Wu J. Shi J. Goedert J.J. Hayes R.B. Yang L. Human gut microbiome and risk for colorectal cancer. J. Natl. Cancer Inst. 2013 105 24 1907 1911 10.1093/jnci/djt300 24316595
    [Google Scholar]
75. Arthur J.C. Perez-Chanona E. Mühlbauer M. Tomkovich S. Uronis J.M. Fan T-J. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012 338 6103 120 3 10.1126/science.1224820
    [Google Scholar]
76. Park C.H. Eun C.S. Han D.S. Intestinal microbiota, chronic inflammation, and colorectal cancer. Intest. Res. 2018 16 3 338 345 10.5217/ir.2018.16.3.338 30090032
    [Google Scholar]
77. Keku T.O. McCoy A.N. Azcarate-Peril A.M. Fusobacterium spp. and colorectal cancer: Cause or consequence? Trends Microbiol. 2013 21 10 506 508 10.1016/j.tim.2013.08.004 24029382
    [Google Scholar]
78. Rubio C.A. Schmidt P.T. Severe defects in the macrophage barrier to gut microflora in inflammatory bowel disease and colon cancer. Anticancer Res. 2018 38 7 3811 3815 10.21873/anticanres.12664 29970500
    [Google Scholar]
79. Poggi A. Benelli R. Venè R. Costa D. Ferrari N. Tosetti F. Zocchi M.R. Human gut-associated natural killer cells in health and disease. Front. Immunol. 2019 10 961 10.3389/fimmu.2019.00961 31130953
    [Google Scholar]
80. Zhu W. Miyata N. Winter M.G. Arenales A. Hughes E.R. Spiga L. Kim J. Sifuentes-Dominguez L. Starokadomskyy P. Gopal P. Byndloss M.X. Santos R.L. Burstein E. Winter S.E. Editing of the gut microbiota reduces carcinogenesis in mouse models of colitis-associated colorectal cancer. J. Exp. Med. 2019 216 10 2378 2393 10.1084/jem.20181939 31358565
    [Google Scholar]
81. Peng C. Ouyang Y. Lu N. Li N. The NF-κB signaling pathway, the microbiota, and gastrointestinal tumorigenesis: Recent advances. Front. Immunol. 2020 11 1387 10.3389/fimmu.2020.01387
    [Google Scholar]
82. Jones R.M. Neish A.S. Gut microbiota in intestinal and liver disease. Annu. Rev. Pathol. 2021 16 1 251 275 10.1146/annurev‑pathol‑030320‑095722 33234022
    [Google Scholar]
83. Ohtani N. Hara E. Gut‐liver axis‐mediated mechanism of liver cancer: A special focus on the role of gut microbiota. Cancer Sci. 2021 112 11 4433 4443 10.1111/cas.15142 34533882
    [Google Scholar]
84. Giraud J. Saleh M. Host–microbiota interactions in liver inflammation and cancer. Cancers (Basel) 2021 13 17 4342 10.3390/cancers13174342 34503151
    [Google Scholar]
85. Ponziani F. Bhoori S. Petito V. Sterbini F.P. Morelli D. Michele T.D. Sanguinetti M. Gasbarrini A. Mazzaferro V. Pompili M. Increased intestinal permeability and inflammation are associated with hepatocellular carcinoma in patients with NAFLD-related liver cirrhosis. J. Hepatol. 2018 68 S432 10.1016/S0168‑8278(18)31104‑8
    [Google Scholar]
86. Zhang N. Gou Y. Liang S. Chen N. Liu Y. He Q. Zhang J. Dysbiosis of gut microbiota promotes hepatocellular carcinoma progression by regulating the immune response. J. Immunol. Res. 2021 2021 1 13 10.1155/2021/4973589 34722779
    [Google Scholar]
87. Ren Z. Li A. Jiang J. Zhou L. Yu Z. Lu H. Xie H. Chen X. Shao L. Zhang R. Xu S. Zhang H. Cui G. Chen X. Sun R. Wen H. Lerut J.P. Kan Q. Li L. Zheng S. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 2019 68 6 1014 1023 10.1136/gutjnl‑2017‑315084 30045880
    [Google Scholar]
88. Pourali G. Zafari N. Velayati M. Mehrabadi S. Maftooh M. Hassanian S.M. Ghayour Mobarhan M. Ferns G.A. Avan A. Khazaei M. Therapeutic potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in pancreatic cancer. Curr. Drug Targets 2023 24 17 1335 1345 10.2174/0113894501264450231129042256 38053355
    [Google Scholar]
89. Khojasteh-Leylakoohi F. Khalili-Tanha G. Sardarzadeh N. Khalili-Tanha N. Dashtiahangar M. Mehrabadi S. Association of a genetic variant in the adenosine triphosphate transmembrane glycoprotein and risk of pancreatic cancer. Ann Pancreat Cancer 2023 6 10.21037/apc‑22‑7
    [Google Scholar]
90. Karpiński T.M. The microbiota and pancreatic cancer. Gastroenterol. Clin. North Am. 2019 48 3 447 464 10.1016/j.gtc.2019.04.008 31383281
    [Google Scholar]
91. Pourali G. Donyadideh G. Mehrabadi S. Hamid F. Hassanian S.M. Ferns G.A. Clinical practice guidelines for interventional treatment of pancreatic cancer. Recent Advances in Nanocarriers for Pancreatic Cancer Therapy Academic Press 2024 345 373 10.1016/B978‑0‑443‑19142‑8.00008‑5
    [Google Scholar]
92. Perkhofer L. Gout J. Roger E. Kude de Almeida F. Baptista Simões C. Wiesmüller L. Seufferlein T. Kleger A. DNA damage repair as a target in pancreatic cancer: State-of-the-art and future perspectives. Gut 2021 70 3 606 617 10.1136/gutjnl‑2019‑319984 32855305
    [Google Scholar]
93. Daniluk J. Liu Y. Deng D. Chu J. Huang H. Gaiser S. Cruz-Monserrate Z. Wang H. Ji B. Logsdon C.D. An NF-κB pathway–mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J. Clin. Invest. 2012 122 4 1519 1528 10.1172/JCI59743 22406536
    [Google Scholar]
94. Ochi A. Graffeo C.S. Zambirinis C.P. Rehman A. Hackman M. Fallon N. Barilla R.M. Henning J.R. Jamal M. Rao R. Greco S. Deutsch M. Medina-Zea M.V. Saeed U.B. Ego-Osuala M.O. Hajdu C. Miller G. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J. Clin. Invest. 2012 122 11 4118 4129 10.1172/JCI63606 23023703
    [Google Scholar]
95. Zambirinis C.P. Pushalkar S. Saxena D. Miller G. Pancreatic cancer, inflammation, and microbiome. Cancer J. 2014 20 3 195 202 10.1097/PPO.0000000000000045 24855007
    [Google Scholar]
96. Beaton L. Freeman R. Humphris G. Why are people afraid of the dentist? Observations and explanations. Med. Princ. Pract. 2014 23 4 295 301 10.1159/000357223 24356305
    [Google Scholar]
97. Huang Q. Li J. Zheng J. Wei A. The carcinogenic role of the notch signaling pathway in the development of hepatocellular carcinoma. J. Cancer 2019 10 6 1570 1579 10.7150/jca.26847 31031867
    [Google Scholar]
98. Peters G.J. Drug resistance in colorectal cancer: General aspects. Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies 2020 1 33 10.1016/B978‑0‑12‑819937‑4.00001‑7
    [Google Scholar]
99. Xiao Q. Lu W. Kong X. Shao Y.W. Hu Y. Wang A. Bao H. Cao R. Liu K. Wang X. Wu X. Zheng S. Yuan Y. Ding K. Alterations of circulating bacterial DNA in colorectal cancer and adenoma: A proof-of-concept study. Cancer Lett. 2021 499 201 208 10.1016/j.canlet.2020.11.030 33249197
    [Google Scholar]
100. Chen F. Dai X. Zhou C.C. Li K. Zhang Y. Lou X.Y. Zhu Y.M. Sun Y.L. Peng B.X. Cui W. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut 2022 71 7 1315 1325 10.1136/gutjnl‑2020‑323476 34462336
     [Google Scholar]
101. Liu L. Zhang J. Miao X. Progress of research on the environmental and genetic influencing factors of colorectal cancer. Zhonghua Liu Xing Bing Xue Za Zhi 2020 41 10 1745 1750 10.3760/cma.j.cn112338‑20200401‑00498.
     [Google Scholar]
102. Kanter-Smoler G. Fritzell K. Rohlin A. Engwall Y. Hallberg B. Bergman A. Meuller J. Grönberg H. Karlsson P. Björk J. Nordling M. Clinical characterization and the mutation spectrum in Swedish adenomatous polyposis families. BMC Med. 2008 6 1 10 10.1186/1741‑7015‑6‑10 18433509
     [Google Scholar]
103. Liang S. Mao Y. Liao M. Xu Y. Chen Y. Huang X. Wei C. Wu C. Wang Q. Pan X. Tang W. Gut microbiome associated with APC gene mutation in patients with intestinal adenomatous polyps. Int. J. Biol. Sci. 2020 16 1 135 146 10.7150/ijbs.37399 31892851
     [Google Scholar]
104. Yamamoto S. Kinugasa H. Hirai M. Terasawa H. Yasutomi E. Oka S. Ohmori M. Yamasaki Y. Inokuchi T. Harada K. Hiraoka S. Nouso K. Tanaka T. Teraishi F. Fujiwara T. Okada H. Heterogeneous distribution of Fusobacterium nucleatum in the progression of colorectal cancer. J. Gastroenterol. Hepatol. 2021 36 7 1869 1876 10.1111/jgh.15361 33242360
     [Google Scholar]
105. Song Y. Xiang Z. Lu Z. Su R. Shu W. Sui M. Wei X. Xu X. Identification of a brand intratumor microbiome signature for predicting prognosis of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2023 149 13 11319 11332 10.1007/s00432‑023‑04962‑1 37380815
     [Google Scholar]
106. Li J.J. Zhu M. Kashyap P.C. Chia N. Tran N.H. McWilliams R.R. Bekaii-Saab T.S. Ma W.W. The role of microbiome in pancreatic cancer. Cancer Metastasis Rev. 2021 40 3 777 789 10.1007/s10555‑021‑09982‑2 34455517
     [Google Scholar]
107. Merali N. Chouari T. Kayani K. Rayner C.J. Jiménez J.I. Krell J. Giovannetti E. Bagwan I. Relph K. Rockall T.A. Dhillon T. Pandha H. Annels N.E. Frampton A.E. A comprehensive review of the current and future role of the microbiome in pancreatic ductal adenocarcinoma. Cancers (Basel) 2022 14 4 1020 10.3390/cancers14041020 35205769
     [Google Scholar]